World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
42004
World Ranking
12933
National Ranking
6612

Overview

Tomasz M. Beer is affiliated with Oregon Health & Science University in the United States. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology, with a significant emphasis on oncology-related subfields.

The main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

The subfields of their work comprise:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Tomasz M. Beer's research topics cover several areas related to cancer and its treatment:

  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Cancer survivorship and care
  • Colorectal Cancer Screening and Detection

The scientist has contributed to numerous publications in important venues, with the most frequent being:

  • Journal of Clinical Oncology
  • ONCOLOGY
  • European Urology
  • Cancer Research
  • Clinical Cancer Research

Some of the notable recent papers include:

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, 2021, New England Journal of Medicine
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • The DNA methylation landscape of advanced prostate cancer, 2020, Nature Genetics
  • Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study, 2023, The Lancet
  • Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance, 2020, Proceedings of the National Academy of Sciences

Frequent collaborators in their research include:

  • Eric J. Small
  • Felix Y. Feng
  • Martin Gleave
  • Rahul Aggarwal
  • Joshi J. Alumkal

Best Publications

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

    Chris Tran;Samedy Ouk;Nicola J. Clegg;Yu Chen

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

    Howard I Scher;Tomasz M Beer;Celestia S Higano;Aseem Anand

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

  • Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

    Yu Sun;Judith Campisi;Judith Campisi;Celestia Higano;Celestia Higano;Tomasz M Beer

  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

    David A. Quigley;Ha X. Dang;Shuang G. Zhao;Paul Lloyd

  • Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

    Rahul Aggarwal;Jiaoti Huang;Joshi J. Alumkal;Li Zhang

  • How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30

    Erik K. Fromme;Kristine M. Eilers;Motomi Mori;Yi Ching Hsieh

  • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

    S. F. Slovin;C. S. Higano;O. Hamid;S. Tejwani

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

    Tomasz M. Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

    Meng Lei Zhu;Craig M. Horbinski;Mark Garzotto;David Z. Qian

  • Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

    Alexander W Wyatt;Matti Annala;Rahul Aggarwal;Kevin Beja

  • Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

    Julie N. Graff;Joshi J. Alumkal;Charles G. Drake;George V. Thomas

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

Frequent Co-Authors

Celestia S. Higano
Celestia S. Higano University of Washington
Eric J. Small
Eric J. Small University of California, San Francisco
George Thomas
George Thomas Oregon Health & Science University
Martin E. Gleave
Martin E. Gleave University of British Columbia
Cora N. Sternberg
Cora N. Sternberg Cornell University
Kim N. Chi
Kim N. Chi BC Cancer Agency
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Bertrand Tombal
Bertrand Tombal Université Catholique de Louvain

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re inspired by medicine but want alternative pathways or further specialization, there are flexible online options to consider. Healthcare administration is crucial to the medical field, and earning a degree through cahme accredited MHA programs ensures your education meets high accreditation standards and opens doors to healthcare leadership roles.

For registered nurses seeking to advance their qualifications, online rn to bsn programs without clinical requirements offer a fast and convenient way to gain a bachelor’s degree, allowing working professionals to balance study with employment. Those aiming for the highest level of clinical practice can accelerate their journey with accelerated dnp programs, helping nurses move quickly into leadership, education, or advanced practice roles.

Additionally, students interested in completing their doctorate swiftly can explore options like the shortest dnp program, designed for efficiency without compromising academic rigor. These flexible online degrees and pathways help students reach their career goals while fitting education around their lives.

Best Scientists Citing Tomasz M. Beer

Trending Scientists